

Leda Leme Talib

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12111959/publications.pdf>

Version: 2024-02-01

45
papers

823
citations

687363

13
h-index

552781

26
g-index

48
all docs

48
docs citations

48
times ranked

1707
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical Exercise in MCI Elderly Promotes Reduction of Pro-Inflammatory Cytokines and Improvements on Cognition and BDNF Peripheral Levels. <i>Current Alzheimer Research</i> , 2014, 11, 799-805.	1.4	150
2	Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 774-780.	2.6	116
3	Higher Serum sTNFR1 Level Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1305-1311.	2.6	85
4	Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 423-429.	2.6	71
5	Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 550-555.	2.6	56
6	Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2015, 17, 326-332.	3.4	50
7	Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. <i>Journal of Psychiatric Research</i> , 2010, 44, 917-920.	3.1	49
8	Platelet GSK3B activity in patients with late-life depression: Marker of depressive episode severity and cognitive impairment?. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 216-222.	2.6	42
9	Cognitive Reserve Relates to Functional Network Efficiency in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 255.	3.4	30
10	Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 963-972.	3.2	27
11	Cognitive and structural cerebral changes in amnesic mild cognitive impairment due to Alzheimer's disease after multicomponent training. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 473-480.	3.7	25
12	Kynurenine is correlated with IL-1 β in plasma of schizophrenia patients. <i>Journal of Neural Transmission</i> , 2018, 125, 869-873.	2.8	18
13	Intranetwork and internetwork connectivity in patients with Alzheimer disease and the association with cerebrospinal fluid biomarker levels. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 366-377.	2.4	17
14	Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity in Cultured Cortical and Hippocampal Neurons. <i>Molecules</i> , 2015, 20, 19878-19885.	3.8	14
15	Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1445-1451.	2.6	14
16	Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 501-507.	3.2	13
17	The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects. <i>PLoS ONE</i> , 2015, 10, e0136141.	2.5	11
18	Higher proportion of inactive Gsk3 β in platelets of elderly patients with bipolar disorder: an effect of treatment?. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 274-278.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Antipsychotic drugs decrease iPLA 2 gene expression in schizophrenia. Schizophrenia Research, 2013, 147, 203-204.	2.0	7
20	Glycogen Synthase Kinase-3 β : Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals. Neuropsychobiology, 2016, 73, 108-115.	1.9	5
21	Glycogen synthase kinase-3 β activity and cognitive functioning in patients with bipolar I disorder. European Neuropsychopharmacology, 2018, 28, 361-368.	0.7	4
22	P1404: APOE Genotype Modifies The Effects of Aerobic Training on Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P588.	0.8	2
23	[P1436]: EFFECTS OF AEROBIC EXERCISE ON PROGRESSION OF HIPPOCAMPAL VOLUME AND COGNITION IN AMNESTIC MILD COGNITIVE IMPAIRMENT DUE TO AD. Alzheimer's and Dementia, 2017, 13, P389.	0.8	2
24	Differences in structural and functional default mode network connectivity in amyloid positive mild cognitive impairment: a longitudinal study. Neuroradiology, 2022, 64, 141-150.	2.2	2
25	[P1421]: SPERMINE AS A POTENTIAL PERIPHERAL BIOMARKER OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1017.	0.8	1
26	[P1413]: SYSTEMIC INFLAMMATION AND ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P985.	0.8	1
27	P4-031: PLATELET APP RATIO IN AD PATIENTS TREATED WITH DONEPEZIL. , 2014, 10, P794-P794.		0
28	P1417: Donepezil Modulates Adam10 and Bace1 Expression in Platelets of Alzheimer's Disease Patients. Alzheimer's and Dementia, 2016, 12, P459.	0.8	0
29	[P1421]: LIPID METABOLITE PLASMA LEVELS AS BIOMARKERS OF EARLY ONSET ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P1017.	0.8	0
30	[P1423]: DONEPEZIL EFFECTS ON CHOLESTEROL AND OXYESTEROLS PLASMA LEVELS OF ALZHEIMER'S DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P333.	0.8	0
31	[P1427]: DEPRESSION AND CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S PATHOLOGY IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P799.	0.8	0
32	[P1421]: PLASMATIC METABOLITES PREDICT CONVERSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1027.	0.8	0
33	[P1429]: ARE CEREBROSPINAL FLUID BIOMARKERS A USEFUL TOOL TO DISCRIMINATE PATIENTS WITH MILD COGNITIVE IMPAIRMENT FROM HEALTHY INDIVIDUALS WITH NO COGNITIVE DETERIORATION?. Alzheimer's and Dementia, 2017, 13, P1056.	0.8	0
34	[P1415]: COMORBIDITIES IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT WERE NOT RELATED TO AD PATHOLOGY ACCORDING TO CEREBROSPINAL FLUID BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P1315.	0.8	0
35	Differences in structural and functional DMN connectivity in amyloid positive AMCI who converted to AD dementia. Alzheimer's and Dementia, 2020, 16, e041219.	0.8	0
36	Differences in functional connectivity in mild cognitive impairment for amyloid positive versus SNAP. Alzheimer's and Dementia, 2020, 16, e042600.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Hippocampal connectivity may predict cholinesterase inhibitors response in mild Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042675.	0.8	0
38	Protein levels of APP, ADAM10 and BACE1 in aging adults with Down syndrome: Preliminary findings. <i>Alzheimer's and Dementia</i> , 2020, 16, e043190.	0.8	0
39	Platelet APP ratio correlates with CSF levels of A β 42 in Alzheimer's disease patients. <i>Alzheimer's and Dementia</i> , 2020, 16, e043212.	0.8	0
40	Platelet APP levels from subjects with Alzheimer's disease and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e043436.	0.8	0
41	Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: A mass spectrometry study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043519.	0.8	0
42	Alzheimer's disease: Donepezil effects on cholesterol and oxysterol plasma levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e044144.	0.8	0
43	Use of a Bayesian Network Model to predict psychiatric illness in individuals with at risk mental states from a general population cohort. <i>Neuroscience Letters</i> , 2021, 770, 136358.	2.1	0
44	Senescence biomarkers in adults and elderly with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
45	Pattern of proteolytic processing of Amyloid Precursor Protein in Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0